By Feng Qirong

On 27th July, good news came from Macau: Nantong intangible cultural heritage medicine ‘Wangshi Baochi Pill’ completed the registration and settlement of traditional Chinese patent medicine in Macau.

It not only marks that Wangshi Baochi Pill has obtained the qualification to enter the Macau market,but also paves the way for radiati ng Portuguese-speaking countries with Macau as a ‘bridgehead’.

Wangshi Baochi Pill, which is known as the ‘No.1 pill in China’, has significant therapeutic effects on digestive system and respiratory system diseases, covering the entire life cycle. In the past more than ten years, Jinghua Pharmaceutical has continued to deepen pharmacological research, worked together with Harvard Medical School, Peking University, etc., revealed the pharmacological mechanism of Wangshi Baochi Pill in gastrointestinal dynamics and intestinal flora.

【背景阅读】

王氏保赤丸在澳门上市

    7月27日，在澳门传来喜讯：南通非遗名药“王氏保赤丸”完成在澳门的中成药注册、落地。

    这不仅标志着王氏保赤丸取得了进军澳门市场的资格，更为以澳门为“桥头堡”辐射葡语系国家铺平了道路。

    被誉为“中华第一丸”的王氏保赤丸，对消化系统、呼吸系统疾病疗效显著，覆盖全生命周期。十多年来，精华制药持续深化药理研究，携手哈佛医学中心、北京大学等，揭示了王氏保赤丸在胃肠动力和肠道菌群方面的药理作用机制。